

Riccardo Nevola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8770120/publications.pdf>

Version: 2024-02-01

46
papers

1,330
citations

393982

19
h-index

360668

35
g-index

46
all docs

46
docs citations

46
times ranked

1840
citing authors

#	ARTICLE	IF	CITATIONS
1	Bedside ultrasound as a screening test for the diagnosis of catheter-related bloodstream infection (CRBI). <i>Journal of Ultrasound</i> , 2022, 25, 1-7.	0.7	4
2	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	1.0	10
3	Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 0106.	0.5	15
4	Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. <i>Scientific Reports</i> , 2022, 12, 5771.	1.6	7
5	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic? Standardized National Screening or One Tailored to Local Epidemiology?. <i>Biology</i> , 2022, 11, 609.	1.3	7
6	Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early) Tj ETQq0 0 0 rgBT /Overlock 10,3Tf 50 542	1.0	3
7	Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. <i>Biology</i> , 2022, 11, 805.	1.3	2
8	Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic. <i>Biology</i> , 2022, 11, 800.	1.3	2
9	Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. <i>Viruses</i> , 2022, 14, 1096.	1.5	9
10	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. <i>Processes</i> , 2021, 9, 135.	1.3	62
11	Factors Enhancing Treatment of Hepatitis C Virusâ€“Infected Italian People Who Use Drugs: The CLEO-GRECA Experience. <i>American Journal of Gastroenterology</i> , 2021, 116, 1248-1255.	0.2	5
12	Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 643-656.	1.4	8
13	Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. <i>Minerva Medica</i> , 2021, 112, 188-200.	0.3	13
14	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. <i>Cardiovascular Diabetology</i> , 2021, 20, 145.	2.7	91
15	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353.	1.1	40
16	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. <i>PLoS ONE</i> , 2021, 16, e0256903.	1.1	8
17	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. <i>Life</i> , 2021, 11, 17.	1.1	6
18	A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. <i>Viruses</i> , 2021, 13, 2249.	1.5	42

#	ARTICLE	IF	CITATIONS
19	Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development. <i>Journal of Hepatology</i> , 2020, 73, S623-S624.	1.8	0
20	Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. <i>JGH Open</i> , 2020, 4, 713-721.	0.7	18
21	Unusual liver-related heart injury. <i>JGH Open</i> , 2020, 4, 1240-1241.	0.7	0
22	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2408-2416.	2.2	58
23	Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1806-1812.	1.1	2
24	The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-8.	1.0	106
25	Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience. <i>Journal of Hepatology</i> , 2020, 73, S366.	1.8	0
26	Metformin: An old drug against old age and associated morbidities. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 108025.	1.1	64
27	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020, 296, 40-47.	0.4	78
28	Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. <i>PLoS ONE</i> , 2020, 15, e0243700.	1.1	36
29	Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	37
30	Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. <i>Nutrients</i> , 2019, 11, 1878.	1.7	14
31	Metformin lactic acidosis: Should we still be afraid?. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107879.	1.1	30
32	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , 2019, 17, 292.	1.8	49
33	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3013-3019.	1.1	33
34	Validation of the BAP-65 score for prediction of in-hospital death or use of mechanical ventilation in patients presenting to the emergency department with an acute exacerbation of COPD: a retrospective multi-center study from the Italian Society of Emergency Medicine (SIMEU). <i>European Journal of Internal Medicine</i> , 2019, 61, 62-68.	1.0	5
35	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24.	1.8	98
36	Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 31.	0.4	0

#	ARTICLE	IF	CITATIONS
37	COPD exacerbations in the emergency department: Epidemiology and related costs. A retrospective cohort multicentre study from the Italian Society of Emergency Medicine (SIMEU). <i>European Journal of Internal Medicine</i> , 2018, 51, 74-79.	1.0	13
38	Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1379-1382.	1.4	64
39	Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?. <i>World Journal of Gastroenterology</i> , 2018, 24, 4617-4621.	1.4	31
40	Endotoxemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. <i>Infection</i> , 2018, 46, 793-799.	2.3	15
41	How does antiviral therapy for hepatitis B influence liver stiffness?. <i>Future Virology</i> , 2018, 13, 521-523.	0.9	0
42	Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease. <i>Hepatoma Research</i> , 2018, 4, 55.	0.6	13
43	Chronic Hepatitis C Virus Infection and Depression. <i>Clinics in Liver Disease</i> , 2017, 21, 517-534.	1.0	46
44	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1458.	1.4	38
45	Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. <i>World Journal of Gastroenterology</i> , 2015, 21, 2269.	1.4	134
46	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. <i>World Journal of Hepatology</i> , 2014, 6, 677.	0.8	14